In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Relypsa brings in $33mm through Series A

Executive Summary

Amgen's Ilypsa subsidiary has spun-off Relypsa (polymeric therapeutics for renal and cardiovascular diseases). The company has raised $33mm through the closing of its Series A venture round. 5AM Ventures and New Leaf Venture Partners led the financing and were joined by the Sprout Group, Delphi Ventures, CMEA Ventures, and Mediphase Venture Partners.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies